Ying Jin

7PUBLICATIONS
53CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 05, 2026
Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.

|Jun 02, 2025
Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors.

Min Wang, Yanxing Chen, Lin Tian

|Feb 13, 2025
Signature Construction Associated with Tumor-Infiltrating Macrophages Identifies IRF8 as a Novel Biomarker for Immunotherapy in Advanced Gastric Cancer.

Wanqian Liao, Yu Wang, Rui Wang

|Sep 01, 2024
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation.

Ying Jin, Run-Jie Huang, Wen-Long Guan

|Mar 04, 2024
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.

Feng Wang, Ying Jin, Min Wang

|Aug 05, 2022
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study).

Feng Wang, Ming-Ming He, Jian Xiao

Pageof 2

Frequent Collaborators

5 joint publications

Feng Wang

5 joint publications

Rui-Hua Xu

3 joint publications

Qi Zhao

2 joint publications

Ji-Bin Li